Business
Soligenix Announces Pricing of $7.5 Million Public Offering
Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its "reasonable best efforts" public offering with existing and certain healthcare focused institutional investors for the purchase and sale of 5,555,560 shares of common stock of the Company (or common stock equivalents in lieu thereof) and warrants to p
About this update from Soligenix, Inc.
[{"type":"text","content":"PRINCETON, N.J., Sept. 26, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its "reasonable best efforts" public offering with existing and certain healthcare focused institutional investors for the purchase and sale of 5,555,560 shares of common stock of the Company (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,555,560 shares of common stock at a combined purchase price of $1.35 per share and accompanying warrant (the "Offering"). The warrants will have an exercise price of $1.35 per share, will be exercisable immediately and will expire five years from the issuance date.","length":869,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Soligenix, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Soligenix, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":112,"url":"https://media.zenfs.com/en/prnewswire.com/85ba4191e64f574a13cd0c133f4a3048"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0bSTAeYRTNnLNEjUJiiRHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/85ba4191e64f574a13cd0c133f4a3048","width":400,"height":112}},"href":"https://mma.prnewswire.com/media/1768046/Soligenix_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Company also has agreed that certain existing May 2023, April 2024 and July 2024 warrants (together, the "Existing Warrants") to purchase an aggregate of 1,162,064 shares of common stock will be amended such that the Existing Warrants will have a reduced exercise price of $1.35 per share and shall expire commensurate with the warrants sold in the Offering.","length":372,"tagName":"p"},{"type":"text","content":"The closing of the Offering is expected to occur on or about September 29, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $7.5 million, before deducting placement agent fees and other estimated Offering expenses. The Company intends to use the net proceeds of this Offering to fund research ...